Adial Pharmaceuticals Q1 EPS $(2.19) Misses $(0.35) Estimate
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals (NASDAQ:ADIL) reported a Q1 EPS of $(2.19), significantly missing the analyst consensus estimate of $(0.35) by 525.71%. This represents a 20.36% improvement over the $(2.75) loss per share from the same period last year.

May 15, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adial Pharmaceuticals reported a Q1 EPS of $(2.19), missing the analyst estimate of $(0.35) by a wide margin. Despite the significant miss, the loss per share improved by 20.36% compared to the same period last year.
The significant miss on EPS estimates is likely to negatively impact investor sentiment and the stock price in the short term. However, the improvement in loss per share compared to last year may provide a slight cushion.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100